nach oben

Erschienen in:

01.09.2023 | Original Paper

The Schiff base hydrazine copper(II) complexes induce apoptosis by P53 overexpression and prevent cell migration through protease-independent pathways

verfasst von: Vahid Asghariazar, Mohammad Amini, Zahra Pirdel, Roghayeh Fekri, Asadollah Asadi, Kazem Nejati-Koshki, Behzad Baradaran, Yasin Panahi

Erschienen in: Medical Oncology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Although chemotherapy has increased the life expectancy of cancer patients, its toxic side effects remain a major challenge. Recently, organometallic compounds, such as Schiff base copper complexes, have become promising candidates for next-generation anticancer drugs owing to their unique anticancer activities. In this study, binuclear copper(II) complex-1 and mononuclear copper(II) complex-2 were examined to analyze their anticancer mechanisms further. For this purpose, a viability test, flow cytometry analysis of apoptosis and the cell cycle, migration assay, and gene expression analysis were performed. According to our results, complex-1 was more cytotoxic than complex-2 at 24/48-h intervals. Our findings also demonstrated that both complexes induced apoptosis at IC₅₀ concentrations and arrested the cell cycle at the G1-S checkpoint. However, complex-1 accelerates cell cycle arrest at the sub-G0/G1 phase more than complex-2 does. Furthermore, gene expression analysis showed that only complex-1 induces the expression of p53. Interestingly, both complexes induced Bcl-2 overexpression. However, they did not affect MMP-13 expression. More interestingly, both complexes inhibited cell migration in different ways, including amoeboid and collective, by recruiting protease-independent pathways. This study confirmed that adding several metal cores and co-ligands increased the activity of the complex. It also appeared that Cu-containing complexes could prevent the migration of cancer cells through protease-independent pathways, which can be used for novel therapeutic purposes.

Nur mit Berechtigung zugänglich

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034370. https://doi.org/10.1177/20503121211034366.CrossRefPubMedPubMedCentral

Di X, Bright AT, Bellott R, Gaskins E, Robert J, Holt S, et al. A chemotherapy-associated senescence bystander effect in breast cancer cells. Cancer Biol Ther. 2008;7(6):864–72. https://doi.org/10.4161/cbt.7.6.5861.CrossRefPubMed

Malik MA, Dar OA, Gull P, Wani MY, Hashmi AA. Heterocyclic Schiff base transition metal complexes in antimicrobial and anticancer chemotherapy. Medchemcomm. 2018;9(3):409–36. https://doi.org/10.1039/c7md00526a.CrossRefPubMed

Soroceanu A, Bargan A. Advanced and biomedical applications of Schiff-base ligands and their metal complexes: a review. Crystals. 2022;12(10):1436. https://doi.org/10.3390/cryst12101436.CrossRef

Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C. Advances in copper complexes as anticancer agents. Chem Rev. 2014;114(1):815–62. https://doi.org/10.1021/cr400135x.CrossRefPubMed

Grubman A, White AR. Copper as a key regulator of cell signalling pathways. Expert Rev Mol Med. 2014;16:e11. https://doi.org/10.1017/erm.2014.11.CrossRefPubMed

Mo Q, Deng J, Liu Y, Huang G, Li Z, Yu P, et al. Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity. Eur J Med Chem. 2018;156:368–80. https://doi.org/10.1016/j.ejmech.2018.07.022.CrossRefPubMed

Kergreis A, Lord RM, Pike SJ. Influence of ligand and nuclearity on the cytotoxicity of cyclometallated C^N^C platinum(II) complexes. Chemistry. 2020;26(65):14938–46. https://doi.org/10.1002/chem.202002517.CrossRefPubMedPubMedCentral

10.

Fekri R, Salehi M, Asadi A, Kubicki M. DNA/BSA interaction, bio-activity, molecular docking simulation study and electrochemical properties of hydrazone Schiff base derived Cu(II)/Ni(II) metal complexes: Influence of the nuclearity and metal ions. Polyhedron. 2017;128:175–87. https://doi.org/10.1016/j.poly.2017.02.047.CrossRef

11.

Fekri R, Salehi M, Asadi A, Kubicki M. Synthesis, characterization, anticancer and antibacterial evaluation of Schiff base ligands derived from hydrazone and their transition metal complexes. Inorg Chim Acta. 2019;484:245–54. https://doi.org/10.1016/j.ica.2018.09.022.CrossRef

12.

Fekri R, Salehi M, Asadi A, Kubicki M. Spectroscopic studies, structural characterization and electrochemical studies of two cobalt (III) complexes with tridentate hydrazone Schiff base ligands: Evaluation of antibacterial activities, DNA-binding, BSA interaction and molecular docking. Appl Organomet Chem. 2018;32(2):e4019. https://doi.org/10.1002/aoc.4019.CrossRef

13.

Lintz M, Muñoz A, Reinhart-King CA. The mechanics of single cell and collective migration of tumor cells. J Biomech Eng. 2017;139(2):0210051–9. https://doi.org/10.1115/1.4035121.CrossRefPubMedPubMedCentral

14.

Baranwal BP, Tripathi K, Singh AK, Tripathi S. Synthesis and spectral characterization of ternary mixed-vanadyl β-diketonate complexes with Schiff bases. Spectrochim Acta A Mol Biomol Spectrosc. 2012;91:365–9. https://doi.org/10.1016/j.saa.2012.02.017.CrossRefPubMed

15.

Habibi MH, Shojaee E, Nichol GS. Synthesis, spectroscopic characterization and crystal structure of novel NNNN-donor μ-bis(bidentate) tetraaza acyclic Schiff base ligands. Spectrochim Acta A Mol Biomol Spectrosc. 2012;98:396–404. https://doi.org/10.1016/j.saa.2012.08.064.CrossRefPubMed

16.

Madhu V, Sabbani S, Kishore R, Naik IK, Das SK. Mechanical motion in the solid state and molecular recognition: reversible cis–trans transformation of an organic receptor in a solid–liquid crystalline state reaction triggered by anion exchange. CrystEngComm. 2015;17(17):3219–23. https://doi.org/10.1039/C5CE00449G.CrossRef

17.

Adhikary J, Chakraborty P, Das B, Datta A, Dash SK, Roy S, et al. Preparation and characterization of ferromagnetic nickel oxide nanoparticles from three different precursors: application in drug delivery. RSC Adv. 2015;5(45):35917–28. https://doi.org/10.1039/C5RA00642B.CrossRef

18.

Arjmand F, Sayeed F, Muddassir M. Synthesis of new chiral heterocyclic Schiff base modulated Cu(II)/Zn(II) complexes: their comparative binding studies with CT-DNA, mononucleotides and cleavage activity. J Photochem Photobiol B. 2011;103(2):166–79. https://doi.org/10.1016/j.jphotobiol.2011.03.001.CrossRefPubMed

19.

Patel RN, Singh YP, Singh Y, Butcher RJ, Zeller M. Unprecedented copper(II) mediated in situ formation of gem-diol binuclear complexes: a combined experimental and computational study. RSC Adv. 2016;6(109):107379–98. https://doi.org/10.1039/C6RA20367A.CrossRef

20.

Shakdofa MM, Shtaiwi MH, Morsy N, Abdel-rassel T. Metal complexes of hydrazones and their biological, analytical and catalytic applications: A review. Main Group Chem. 2014;13(3):187–218. https://doi.org/10.1002/CHIN.201506320.CrossRef

21.

Graf N, Lippard SJ. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev. 2012;64(11):993–1004. https://doi.org/10.1016/j.addr.2012.01.007.CrossRefPubMedPubMedCentral

22.

Gandin V, Tisato F, Dolmella A, Pellei M, Santini C, Giorgetti M, et al. In vitro and in vivo anticancer activity of copper(I) complexes with homoscorpionate tridentate tris(pyrazolyl)borate and auxiliary monodentate phosphine ligands. J Med Chem. 2014;57(11):4745–60. https://doi.org/10.1021/jm500279x.CrossRefPubMed

23.

Wang T, Guo Z. Copper in medicine: homeostasis, chelation therapy and antitumor drug design. Curr Med Chem. 2006;13(5):525–37. https://doi.org/10.2174/092986706776055742.CrossRefPubMed

24.

Qi J, Liang S, Gou Y, Zhang Z, Zhou Z, Yang F, et al. Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism. Eur J Med Chem. 2015;96:360–8. https://doi.org/10.1016/j.ejmech.2015.04.031.CrossRefPubMed

25.

Desbouis D, Troitsky IP, Belousoff MJ, Spiccia L, Graham B. Copper(II), zinc(II) and nickel(II) complexes as nuclease mimetics. Coord Chem Rev. 2012;256(11):897–937. https://doi.org/10.1016/j.ccr.2011.12.005.CrossRef

26.

Montagner D, Gandin V, Marzano C, Erxleben A. DNA damage and induction of apoptosis in pancreatic cancer cells by a new dinuclear bis(triazacyclonane) copper complex. J Inorg Biochem. 2015;145:101–7. https://doi.org/10.1016/j.jinorgbio.2015.01.013.CrossRefPubMed

27.

Majouga AG, Zvereva MI, Rubtsova MP, Skvortsov DA, Mironov AV, Azhibek DM, et al. Mixed valence copper(I, II) binuclear complexes with unexpected structure: synthesis, biological properties and anticancer activity. J Med Chem. 2014;57(14):6252–8. https://doi.org/10.1021/jm500154f.CrossRefPubMed

28.

Jany T, Moreth A, Gruschka C, Sischka A, Spiering A, Dieding M, et al. Rational design of a cytotoxic dinuclear Cu₂ complex that binds by molecular recognition at two neighboring phosphates of the DNA backbone. Inorg Chem. 2015;54(6):2679–90. https://doi.org/10.1021/ic5028465.CrossRefPubMed

29.

Sinicropi MS, Ceramella J, Iacopetta D, Catalano A, Mariconda A, Rosano C, et al. Metal complexes with Schiff Bases: Data collection and recent studies on biological activities. Int J Mol Sci. 2022;23(23):14840. https://doi.org/10.3390/ijms232314840.CrossRefPubMedPubMedCentral

30.

Marzano C, Pellei M, Tisato F, Santini C. Copper complexes as anticancer agents. Anticancer Agents Med Chem. 2009;9(2):185–211. https://doi.org/10.2174/187152009787313837.CrossRefPubMed

31.

Parasuraman B, Rajendran J, Rangappan R. An insight into antibacterial and anticancer activity of homo and hetero binuclear Schiff Base complexes. Orient J Chem. 2017;33(3):1223.CrossRef

32.

Jiang S, Ni H, Liu F, Gu S, Yu P, Gou Y. Binuclear Schiff base copper (II) complexes: Syntheses, crystal structures, HSA interaction and anti-cancer properties. Inorg Chim Acta. 2020;499: 119186.CrossRef

33.

Fekri R, Abdolmaleki A, Asadi A, Salehi M, Karimian A, Taghizadehmomen L, et al. Anticancer effects of copper (II) hydrazone Schiff base complex: A review. Basic Clin Cancer Res. 2022;13(2):143–55.

34.

Akhmetova VR, Galimova E, Mescheryakova ES, Dzhemileva LU, Dzhemilev UM, D’Yakonov AV. Mono- and binuclear complexes of copper(II) with dimethylaminomethyl derivatives of 2-naphthol and 6-quinolinol: synthesis and in vitro study of antitumor properties. Metallomics. 2023;15(6):mfad037. https://doi.org/10.1093/mtomcs/mfad037.CrossRefPubMed

35.

Zhang Z, Wang H, Yan M, Wang H, Zhang C. Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review). Mol Med Rep. 2017;15(1):3–11. https://doi.org/10.3892/mmr.2016.6022.CrossRefPubMed

36.

Molinaro C, Martoriati A, Pelinski L, Cailliau K. Copper complexes as anticancer agents targeting topoisomerases I and II. Cancers (Basel). 2020;12(10):2863. https://doi.org/10.3390/cancers12102863.CrossRefPubMed

37.

Hussain A, AlAjmi MF, Rehman MT, Amir S, Husain FM, Alsalme A, et al. Copper(II) complexes as potential anticancer and Nonsteroidal anti-inflammatory agents: In vitro and in vivo studies. Sci Rep. 2019;9(1):5237. https://doi.org/10.1038/s41598-019-41063-x.CrossRefPubMedPubMedCentral

38.

Tchounwou PB, Newsome C, Williams J, Glass K. Copper-induced cytotoxicity and transcriptional activation of stress genes in human liver carcinoma (HepG(2)) cells. Met Ions Biol Med. 2008;10:285–90.PubMedPubMedCentral

39.

Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–91. https://doi.org/10.1016/j.cell.2016.11.037.CrossRefPubMedPubMedCentral

40.

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. https://doi.org/10.18632/oncotarget.16723.CrossRefPubMed

41.

Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, et al. Migrastatics-anti-metastatic and anti-invasion drugs: Promises and challenges. Trends Cancer. 2017;3(6):391–406. https://doi.org/10.1016/j.trecan.2017.04.008.CrossRefPubMedPubMedCentral

42.

Balsa LM, Ruiz MC, Santa Maria de la Oarra L, Baran EJ, León IE. Anticancer and antimetastatic activity of copper(II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres. J Inorg Biochem. 2020;204:110975. https://doi.org/10.1016/j.jinorgbio.2019.110975.CrossRefPubMed

43.

Tsymbal S, Li G, Agadzhanian N, Sun Y, Zhang J, Dukhinova M, et al. Recent advances in copper-based organic complexes and nanoparticles for tumor theranostics. Molecules. 2022;27(20):7066. https://doi.org/10.3390/molecules27207066.CrossRefPubMedPubMedCentral

44.

Cucci LM, Satriano C, Marzo T, La Mendola D. Angiogenin and copper crossing in wound healing. Int J Mol Sci. 2021;22(19):10704. https://doi.org/10.3390/ijms221910704.CrossRefPubMedPubMedCentral

45.

Nasulewicz A, Mazur A, Opolski A. Role of copper in tumour angiogenesis–clinical implications. J Trace Elem Med Biol. 2004;18(1):1–8. https://doi.org/10.1016/j.jtemb.2004.02.004.CrossRefPubMed

46.

Ji P, Wang P, Chen H, Xu Y, Ge J, Tian Z, et al. Potential of copper and copper compounds for anticancer applications. Pharmaceuticals. 2023;16(2):234. https://doi.org/10.3390/ph16020234.CrossRefPubMedPubMedCentral

47.

Jia Y, Chen L, Jia Q, Dou X, Xu N, Liao DJ. The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption. J Carcinog. 2016;15:3. https://doi.org/10.4103/1477-3163.182809.CrossRefPubMedPubMedCentral

48.

Feroz W, Sheikh AMA. Exploring the multiple roles of guardian of the genome: P53. Egypt J Med Hum Genet. 2020;21(1):49. https://doi.org/10.1186/s43042-020-00089-x.CrossRef

49.

Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6(3):a026104. https://doi.org/10.1101/cshperspect.a026104.CrossRefPubMedPubMedCentral

50.

Batchelor E, Loewer A, Mock C, Lahav G. Stimulus-dependent dynamics of p53 in single cells. Mol Syst Biol. 2011;7:488. https://doi.org/10.1038/msb.2011.20.CrossRefPubMedPubMedCentral

51.

Geva-Zatorsky N, Rosenfeld N, Itzkovitz S, Milo R, Sigal A, Dekel E, et al. Oscillations and variability in the p53 system. Mol Syst Biol. 2006;2:2006.003. https://doi.org/10.1038/msb4100068.CrossRef

52.

Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science. 2012;336(6087):1440–4. https://doi.org/10.1126/science.1218351.CrossRefPubMedPubMedCentral

53.

El-Emshaty HM, Saad EA, Toson EA, Abdel Malak CA, Gadelhak NA. Apoptosis and cell proliferation: correlation with BCL-2 and P53 oncoprotein expression in human hepatocellular carcinoma. Hepatogastroenterology. 2014;61(133):1393–401. https://doi.org/10.5754/hge13453.CrossRef

54.

Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, et al. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol. 2007;31(4):867–74.PubMed

55.

Li S, Pritchard DM, Yu LG. Regulation and function of matrix metalloproteinase-13 in cancer progression and metastasis. Cancers (Basel). 2022;14(13):3263. https://doi.org/10.3390/cancers14133263.CrossRefPubMed

56.

González-Ballesteros MM, Mejía C, Ruiz-Azuara L. Metallodrugs: An approach against invasion and metastasis in cancer treatment. FEBS Open Bio. 2022;12(5):880–99. https://doi.org/10.1002/2211-5463.13381.CrossRefPubMedPubMedCentral

57.

Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol. 2009;185(1):11–9. https://doi.org/10.1083/jcb.200807195.CrossRefPubMedPubMedCentral

58.

Friedl P, Wolf K. Plasticity of cell migration: A multiscale tuning model. J Cell Biol. 2010;188(1):11–9. https://doi.org/10.1083/jcb.200909003.CrossRefPubMedPubMedCentral

59.

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54. https://doi.org/10.1038/nrc822.CrossRefPubMed

60.

Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int J Mol Sci. 2021;22(23):12827. https://doi.org/10.3390/ijms222312827.CrossRefPubMedPubMedCentral

61.

Crowley LC, Marfell BJ, Scott AP, Waterhouse NJ. Quantitation of apoptosis and necrosis by Annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc. 2016. https://doi.org/10.1101/pdb.prot087288.CrossRefPubMed

62.

Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. Methods Mol Biol. 2004;281:301–11. https://doi.org/10.1385/1-59259-811-0:301.CrossRefPubMed

63.

Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–33. https://doi.org/10.1038/nprot.2007.30.CrossRefPubMed

Titel: The Schiff base hydrazine copper(II) complexes induce apoptosis by P53 overexpression and prevent cell migration through protease-independent pathways
verfasst von: Vahid Asghariazar
Mohammad Amini
Zahra Pirdel
Roghayeh Fekri
Asadollah Asadi
Kazem Nejati-Koshki
Behzad Baradaran
Yasin Panahi
Publikationsdatum: 01.09.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 9/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02150-2

Springer Medizin

The Schiff base hydrazine copper(II) complexes induce apoptosis by P53 overexpression and prevent cell migration through protease-independent pathways

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5

Mechanism of anticancer effect of gambogic acid on gastric signet ring cell carcinoma

Integrative analysis of GWAS and transcriptomics data reveal key genes for non-small lung cancer

Hypoxia-induced PPFIA4 accelerates the progression of ovarian cancer through glucose metabolic reprogramming

Current neoadjuvant therapy for operable locally advanced esophageal cancer

The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie